Oxaliplatin Sandoz (Oxaliplatin)

Oxaliplatin is a platinum‑based chemotherapeutic that interferes with DNA synthesis in several gastrointestinal cancers.

• Colorectal cancer: enhances tumor response when combined with fluoropyrimidine‑based regimens.
• Gastric cancer: used in combination protocols for advanced disease.
• Pancreatic cancer: contributes to disease control as part of multi‑drug regimens.

• Oxaliplatin forms reactive platinum complexes that covalently bind to DNA bases, creating intra‑ and interstrand cross‑links that block DNA replication and transcription. The resulting DNA damage triggers cell‑cycle arrest and apoptosis, preferentially affecting rapidly dividing tumor cells.

Oxaliplatin may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Peripheral neuropathy: tingling or numbness, often dose‑related.
• Nausea and vomiting: may require anti‑emetic support.
• Diarrhea: can be self‑limiting or require treatment.
• Fatigue: generalized tiredness during therapy.
• Elevated liver enzymes: mild transaminase rise.
• Low blood counts: neutropenia or anemia.

Serious or Rare Side Effects

• Severe hypersensitivity reactions: rash, bronchospasm, or anaphylaxis.
• Persistent peripheral neuropathy: long‑lasting sensory deficits.
• Acute hemolytic anemia: rare but potentially life‑threatening.
• Cardiac arrhythmias: uncommon electrocardiographic changes.
• Severe neutropenic infection: febrile neutropenia requiring hospitalization.
• Renal impairment: acute kidney injury in susceptible patients.

When using Oxaliplatin, clinicians should observe several safety measures.

• Renal function: assess baseline creatinine and monitor during therapy.
• Hepatic function: evaluate liver enzymes before each cycle.
• Neuropathy monitoring: conduct regular neurological examinations.
• Hematologic monitoring: perform complete blood counts regularly.
• Hypersensitivity risk: be prepared to manage infusion reactions.
• Store at below 25°C: keep in original container, protect from moisture and light.

Oxaliplatin can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid)

• Concurrent use of other platinum agents: increased risk of cumulative toxicity.
• High‑dose vitamin C infusions: may reduce platinum‑DNA binding.

Moderate Interactions (Monitor Closely)

• Anticoagulants (e.g., warfarin): heightened bleeding risk due to thrombocytopenia.\n- Strong CYP450 inducers: potential alteration of supportive‑care drug levels.
• Nephrotoxic antibiotics (e.g., aminoglycosides): added renal stress.
• Antiemetic regimens containing dopamine antagonists: may potentiate neurotoxicity.
• Electrolyte‑altering agents (e.g., loop diuretics): influence neuropathy severity.